Nuclear factor erythroid-2-related factor 2 (Nrf2) is a potential prognostic factor in patients with gastric adenocarcinoma

Basit Öğe Kaydı
dc.authoridAlakus, Huseyin/0000-0003-2650-7208
dc.contributor.authorAlakus, Huseyin
dc.contributor.authorKaya, Mustafa
dc.contributor.authorOzer, Hatice
dc.contributor.authorEgilmez, Hatice Reyhan
dc.contributor.authorKaradayi, Kursat
dc.date.accessioned2024-10-26T18:09:15Z
dc.date.available2024-10-26T18:09:15Z
dc.date.issued2023
dc.departmentSivas Cumhuriyet Üniversitesi
dc.description.abstractBackground: Gastric cancer is one of the leading causes of cancer-related death, and many researchers are focused on the discovery and use of different biomarkers in prognosis prediction. The use of Nrf2 as a prognostic marker in patients with gastric cancer remains controversial. In this study, we evaluated the expression of Nrf2 protein in gastric adenocarcinoma.Patients and methods: A total of 86 patients who underwent gastric resection and D2 lymph node dissection due to gastric adenocarcinoma were included. Clinicopathological characteristics, such as age, gender, gastrectomy type, pathologic T (pT) and N (pN) stages, tumor grade, tumor type per Lauren's classification, presence of lymphovascular invasion, and Nrf2 expression were evaluated.Results: While pT, pN, and Nrf-2 expression were found to be negative prognostic predictors for overall survival in one-way analysis of variance, Nrf-2 expression was the only significant negative prognostic predictor in multi -variance analysis. pT, pN, diffuse type, high tumor grade, and Nrf-2 expression significantly affected overall survival in Kaplan-Meier survival analyses (p = 0.02, p = 0.03, p < 0.01, p = 0.027, and p = 0.001, respectively).Conclusions: Our findings support that Nrf2 is a prognostic marker in patients with gastric adenocarcinoma. Anti-Nrf2 therapy options should be investigated to improve prognosis in gastric cancer patients.
dc.identifier.doi10.1016/j.ajg.2022.10.010
dc.identifier.endpage10
dc.identifier.issn1687-1979
dc.identifier.issn2090-2387
dc.identifier.issue1
dc.identifier.pmid36400701
dc.identifier.scopus2-s2.0-85142243139
dc.identifier.scopusqualityQ3
dc.identifier.startpage5
dc.identifier.urihttps://doi.org/10.1016/j.ajg.2022.10.010
dc.identifier.urihttps://hdl.handle.net/20.500.12418/30031
dc.identifier.volume24
dc.identifier.wosWOS:000953532300001
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherElsevier
dc.relation.ispartofArab Journal of Gastroenterology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectNF-E2-related factor 2
dc.subjectPrognosis
dc.subjectStomach neoplasms
dc.subjectAdenocarcinoma
dc.subjectGastrectomy
dc.titleNuclear factor erythroid-2-related factor 2 (Nrf2) is a potential prognostic factor in patients with gastric adenocarcinoma
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksyonu
Scopus İndeksli Yayınlar Koleksiyonu